Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31083726 | 0.93 | ESR2 (0.66) | ESR2GPR119NR1H2NPC1RAB9A | |
| SCHEMBL25404045 | 0.93 | ESR2 (0.66) | ESR2GPR119NR1H2NPC1RAB9A | |
| SCHEMBL5467960 | 0.87 | ESR2 (0.68) | ESR2GPR119NR1H2NPC1RAB9A | |
| SCHEMBL22638749 | 0.85 | ROCK2 (0.52) | ESR2GPR119NR1H2PTPN2PTPN1 | |
| SCHEMBL5455730 | 0.83 | GPR119 (0.56) | ESR2GPR119NR1H2NPC1RAB9A | |
| SCHEMBL4763630 | 0.82 | ESR2 (0.50) | ESR2GPR119NR1H2NPC1RAB9A | |
| SCHEMBL5960591 | 0.81 | CHRM4 (0.47) | ESR2GPR119NR1H2PTPN2PTPN1 | |
| SCHEMBL2115820 | 0.80 | GPR119 (0.57) | ESR2GPR119NR1H2NPC1RAB9A | |
| SCHEMBL30593270 | 0.80 | ESR2 (0.69) | ESR2GPR119NR1H2NPC1RAB9A | |
| SCHEMBL23124526 | 0.80 | ESR2 (0.69) | ESR2GPR119NR1H2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1730114-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005087746-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | ESR2 573/4885GPR119 1092/4885NR1H2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.